This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $486,057 to The Trustees of the University of Pennsylvania to develop a novel mRNA gene therapy approach to address challenges in achieving an HIV cure. The research program aims to create an "mRNA-only 'kick and kill' cure strategy" for HIV, leveraging mRNA gene therapy to: 1) deliver the viral protein Tat to drive HIV...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $919,501 to Emmune Inc., a small business located in Cambridge, Massachusetts, to develop a non-viral gene therapy platform using ECD4-IG as a practical approach for suppressing HIV replication long-term after a single intramuscular injection. The funded research aims to establish a "functional cure" for HIV by...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a hematopoietic stem/progenitor cell-based chimeric antigen receptor (CAR) gene therapy approach to functionally cure HIV infection. The University of California, Los Angeles (UCLA) received $343,744 to work towards Investigational New Drug (IND) development and clinical implementation...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $769,737 to Yale University to develop capsid-engineered adeno-associated viral (AAV) vectors that can specifically target and deliver gene therapies to human T cells and myeloid cells. The goal is to use these AAV vectors to deliver a designer recombinase called BREC1, which can eliminate HIV provirus integrated in...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to implement an innovative HIV self-testing and long-acting injectable HIV treatment and prevention intervention for commercial minibus drivers in Nigeria. The $809,692 award to The George Washington University, with sub-awards to Wake Forest University Health Sciences, University of Rochester, Emory...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $194,616.00 to Emory University to develop virus-like particles (VLPs) for an HIV-1 cure strategy. The key objectives are to: Use VLPs to deliver the HIV-1 Tat protein as a latency reversing agent, paired with AAV vectors expressing broadly neutralizing antibodies to eliminate reactivated HIV-infected cells (the...
This Project Grant award, funded by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to develop ultra-long-acting antiretroviral drug formulations for the treatment of HIV-1 infection in pediatric populations. The $2,207,322 award, effective January 17, 2025 through December 31, 2026, supports an innovative approach to transform established oral pediatric therapies, such as...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Research Infrastructure Programs (CFDA 93.351) provides $257,429 to the University of Miami's School of Medicine to study immunomodulatory drug interventions for preventing host immune responses against adeno-associated virus (AAV)-delivered anti-HIV antibodies. The project aims to explore strategies to induce tolerance or prevent immune responses against AAV-delivered broadly neutralizing...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel HIV cure strategy by targeting CD127-expressing tissue reservoir cells. The total funding amount is $250,791.00, with an award date of August 6, 2024 and an ultimate completion date of July 31, 2026. The key products and services to be delivered under this grant include: Utilizing an ex vivo...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $381,487 to the University of Maryland, Baltimore (UMB) to assess the early implementation of long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) at high risk of HIV acquisition in Zambia. The key objectives are to: 1) Evaluate implementation determinants of CAB-LA...